Tandem Mobi® Region 3

Tandem Mobi is the world’s smallest, durable automated insulin delivery system.1 Impressively small and offering next-level convenience and discretion, Tandem Mobi is controllable with a compatible, personal iPhone.*

Use of the Tandem Mobi mobile app requires a prescription. Always consult a healthcare professional for information about how to manage diabetes.

Features

• Mobile Control: The Tandem Mobi system is controllable from a compatible, personal iPhone, offering discreet and convenient access to therapy data and pump functions*

• Advanced Therapy Visualization: View a 24-hour graphical representation of glucose readings (CGM and BGM), basal and bolus events, insulin on board, carbohydrate intake, suspensions, and other therapy-related data

• Pump Status Monitoring: Real-time visibility into pump battery level, available insulin, active Personal Profile, CGM sensor and transmitter status, and more

• Customizable User Experience: Personal Profiles and activity settings allow users to tailor therapy to their lifestyle, with enhanced personalization features

• AutoBolus: The only system with AutoBolus to help with missed meal boluses and preventing hyperglycemia†

• Seamless Data Sync: Wireless data uploads to the Tandem Source platform to ensure therapy data is securely backed up and accessible‡

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE. The electronic instructions for use for the Tandem Mobi mobile app (Basic UDI-DI: 00389152690940) can be accessed through the Tandem Mobi user guide, available here: https://www.tandemdiabetes.com/support/resources/documents. Upon request, a printed copy of the user guide can be provided within seven days at no additional cost.

If the language set on your smartphone is supported by the mobile app, then the mobile app will display in that language. If the language set on your smartphone is not supported by the mobile app, then the mobile app will display in English.

*The mobile app requires a compatible smartphone model and operating system (sold separately). †If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ+ technology calculates an AutoBolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value. ‡Uploads to the Tandem Source platform do not take place in real time and should not be relied upon by healthcare providers, pump users, or caregivers for remote patient monitoring. Standard carrier data rates may apply. Smartphone sold separately.

Reference

1. As of Dec., 2025. Data on file, Tandem Diabetes Care.